Meeting
2024 ASCO Annual Meeting
Association between clinical and disease characteristics and detectable or undetectable baseline ctDNA in patients with metastatic uveal melanoma.
Authors
Paul D. Nathan
Mount Vernon Cancer Centre, Noorthwood, United Kingdom
Paul D. Nathan , Laura Collins , Richard D. Carvajal , Piruntha Thiyagarajah , Ryan J. Sullivan , Joseph J Sacco
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02570308; NCT03070392
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 9537)
DOI
10.1200/JCO.2024.42.16_suppl.9537
Abstract #
9537
Poster Bd #
321
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
First Author: Alexandra Ikeguchi
Poster
2023 ASCO Annual Meeting
Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp.
First Author: Dan Feng
Poster
2023 ASCO Annual Meeting
Survival outcomes associated with liver-directed therapies in patients with metastatic uveal melanoma.
First Author: Michael M Caplan
Poster
2021 ASCO Annual Meeting
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
First Author: Marlana Orloff